Fwd: Craig Venter and Human Longevity, Inc.

Dear GRG Member,

 

Craig Venter and Human Longevity, Inc.

 

Source

Life Extension Magazine

November 2014

High points of article – tried to not leave anything out:

Best to read the whole thing. Link below.

–        Venter launched an ambitious and expensive commercial venture to amass and electronically analyze the medical, genomic, microbiomic, and metabolic data of 40,000 individuals every year. And eventually, 100,000 individuals a year.

–        The goal is to identify biologically relevant patterns in these interconnected data—patterns that may eventually reveal different ways to block the complex interactions that trigger age-related diseases and even aging itself.

–        Costs of genomic sequencing have declined from $100,000 to $1000

–        Low cost sequencing is essential because we need to sequence hundreds of thousands, maybe even millions, of individuals to truly understand how genes influence disease and aging—so that more specifically targeted drugs, treatments, and preventive strategies can be developed.

–        Initially management considers cancer the most likely area of genomic research to deliver immediately actionable results.

–        They plan to also concentrate on diabetes, heart disease, dementia, and liver disease, diseases that the company views as, “some of the most difficult to treat, let alone cure, [the] diseases affecting people as they age.”

–        Venter hired a diverse crew of experts in genomics, stem cells, cancer, translational medicine, the microbiome, and emerging technologies.  

–        He plans to collaborate with companies in the genetics and stem cell arena, with large hospital systems and clinics that will utilize his firm’s services, with pharmaceutical companies that can discover and develop new therapeutics, and with academics.

–        It’s just one leg of Venter’s broader strategic plan.

–        With preliminary funding of $70 million in hand, mostly from wealthy investors, Human Longevity plans to also concentrate on diabetes, heart disease, dementia, and liver disease, diseases that the company views as, “some of the most difficult to treat, let alone cure, [the] diseases affecting people as they age.”

–        Human Longevity will use mass spectrometry to document individuals’ metabolomes—the constantly changing array of small molecules of biochemicals and lipids circulating throughout participants’ bodies.

–        While genome sequencing can reveal information about inherited risk of disease or hint at how long a person will live, metabolic data can clarify how environment, diet, and other factors affect an individual’s health and life span. Metabolic data also help researchers interpret genomic information. Pinpointing a particular gene as important in a disease or a normal cellular process does not, in itself, clarify what that gene actually does. But if a particular metabolite is found to correlate with a particular genetic signal, then researchers can zero-in on the function of the gene. The relevance of blood biochemistry is underscored by the fact these metabolites change as we age—to such an extent that an analysis of blood metabolites can reveal a person’s specific age.

–        However, aging and human cell behavior changes are not the only cause of changes in blood metabolites. The microbes in our bodies—which outnumber human cells 10 to one—generate metabolites that can be detected in the blood.

–        Human Longevity will also be mapping at least some participants’ microbiomes—the complete makeup of the trillions of bacteria, viruses, and fungi living in each individual’s gut, mouth, and other body sites, as well as on the skin.

–        Venter plans to deliver predictive and preventive medicine on a revolutionary scale by discovering the very earliest warning signs for susceptibility to chronic illnesses such as cancer, Alzheimer’s, and heart disease.

–        He envisions blocking the interconnected pathways of these diseases with specific, new interventions tailored to each individual’s distinct profile.

–        Just one way Venter aspires to accomplish this is by translating a web of personalized data into stem cell therapies.

–        He expects to use techniques developed at his existing company, Synthetic Genomics, to rewrite the genetic code of stem cells to correct errors and use stem cell therapy as one of the key adjuvants to changing long-term health and aging outcomes.

–        Human Longevity is going to change the way medicine is practiced by helping to shift to a more preventive, genomic-based medicine model, which we believe will lower healthcare costs.”

–        Extending the number of healthy years will require focusing, not on individual diseases, but on aging.

–        Why aging?

o   “The easiest answer is that aging is a central component of every disease that we want to address therapeutically,” said  Robert Hariri, MD, PhD Vice-Chairman and Co-Founder.  “We believe that many of the processes at the cellular and the genomic level that we call aging are related and connected.”

o   Venter said “Our goal is to make 100 years old the new 60.”

 

http://ift.tt/1MREinr

 

 

John M. “Johnny” Adams

Executive Director Gerontology Research Group

JAdams@grg.org

(650) 265-4969

(949) 922-9786 cell

~~~~

CEO / Exec. Director

Carl I. Bourhenne Medical Research Foundation / Aging Intervention Foundation

http://ift.tt/12PnEEz

http://ift.tt/1yrtxED

 

Advertisements

About Johnny Adams

My full-time commitment is to slow and ultimately reverse age related functional decline to increase healthy years of life. I’ve been active in this area since the 1970s, steadily building skills and accomplishments. I have a good basic understanding of the science of aging, and have many skills that complement those of scientists so they can focus on science to advance our shared mission. Broad experience Top skills: administration, management, information technology (data and programming), communications, writing, marketing, market research and analysis, public speaking, forging ethical win-win outcomes among stakeholders (i.e. high level "selling"). Knowledge in grant writing, fundraising, finance. Like most skilled professionals, I’m best described as a guy who defines an end point, then figures out how to get there. I enjoy the conception, design, execution and successful completion of a grand plan. Executive Director Gerontology Research Group (GRG). Manages Email discussion forum, web site, meetings and oversees supercentenarian (oldest humans, 110+ years) research. CEO / Executive Director Carl I. Bourhenne Medical Research Foundation (Aging Intervention Foundation), an IRS approved 501(c)(3) nonprofit. http://www.AgingIntervention.org Early contributor to Supercentenarian Research Foundation. Co-Founder Geroscience Healthspan Forum. Active contributor to numerous initiatives to increase healthy years of life. Co-authored book on conventional, practical methods available today to slow the processes of aging – nutrition, exercise, behavior modification and motivation, stress reduction, proper supplementation, damage caused by improper programs, risk reduction and others. Fundamental understanding of, and experience in the genomics of longevity (internship analyzing and curating longevity gene papers). Biological and technical includes information technology, software development and computer programming, bioinformatics and protein informatics, online education, training programs, regulatory, clinical trials software, medical devices (CAT scanners and related), hospital electrical equipment testing program. Interpersonal skills – good communication, honest, well liked, works well in teams or alone. Real world experience collaborating in interdisciplinary teams in fast paced organizations. Uses technology to advance our shared mission. Education: MBA 1985 University of Southern California -- Deans List, Albert Quon Community Service Award (for volunteering with the American Longevity Association and helping an elderly lady every other week), George S. May Scholarship, CA State Fellowship. BA psychology, psychobiology emphasis 1983 California State University Fullerton Physiological courses as well as core courses (developmental, abnormal etc). UCLA Psychobiology 1978, one brief but fast moving and fulfilling quarter. Main interest was the electrochemical basis of consciousness. Also seminars at the NeuroPsychiatric Institute. Other: Ongoing conferences, meetings and continuing education. Aging, computer software and information technology. Some molecular biology, biotech, bio and protein informatics, computer aided drug design, clinical medical devices, electronics, HIPAA, fundraising through the Assoc. of Fundraising Professionals. Previous careers include: Marketing Increasing skill set and successes in virtually all phases, with valuable experience in locating people and companies with the greatest need and interest in a product or service, and sitting across the table with decision makers and working out agreements favorable to all. Information Technology: Management, data analysis and programming in commercial and clinical trials systems, and bioinformatics and protein informatics. As IT Director at Newport Beach, CA based technology organization Success Family of Continuing Education Companies, provided online software solutions for insurance and financial professionals in small to Fortune 500 size companies. We were successful with lean team organization (the slower moving competition was unable to create similar software systems). Medical devices: At Omnimedical in Paramount CA developed and managed quality assurance dept. and training depts. for engineers, physicians and technicians. Designed hospital equipment testing program for hospital services division. In my early 20’s I was a musician, and studied psychology and music. Interned with the intention of becoming a music therapist. These experiences helped develop valuable skills used today to advance our shared mission of creating aging solutions.
This entry was posted in Uncategorized and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s